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Rituximab in pemphigus foliaceous with
autoantibodies against both Desmoglein 1
and Desmoglein 3
Pemphigus foliaceous (PF) is generally a benign autoim-
mune blistering disease, but in some patients lesions are
severe with serious implications in life quality. We report a
case of severe PF refractory to standard treatment options
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Figure 1. A) Numerous scaly, crusted erosions localized on the face. B) Complete remission sustained after a 12 month follow-up
period. C) Time evolution of patient severity index (mild if less than 5, moderate if 5 to 7, and severe if higher than 7) [1], levels
of antibodies to desmoglein 1 and desmoglein 3 (normal value < 20 UI/mL), and percentage of circulating CD20+ B cells.
A 26-year-old black male with a 1-year history of PF
was treated with systemic prednisolone (up to 80 mg/day)
and azatioprine (100 mg/day) for 9 months. Despite the
immunosuppressant therapy, he still presented a high
severity index [1], with numerous scaly, crusted erosions
localized on the face and trunk (ﬁgure 1A). No lesions
were found on mucosal surfaces. A skin biopsy showed
clefting in the upper spinous layer. Direct immunofluores-
cence showed immunoglobulin G deposits in intercellular
space, mainly in the spinous layer. Circulating levels of
anti-Dsg1 and anti-Dsg3 IgG antibodies were measured
in serum samples by a commercially available enzyme-
linked immunosorbent assay (ELISA) and elevated levels
of both were found. The patient was then treated with
one cycle of four weekly infusions of rituximab at a dose
of 375 mg/m2 of body surface area on days 1, 8, 15 and
22. Azatioprine was stopped after the first infusion. The
prednisolone dosage was tapered. The patient experienced
clinical improvement that was evident immediately after
the last infusion, with healing of all lesions after 2 months.
With a 12 month follow-up period completed, dramatic clin-
ical improvement was sustained (ﬁgure 1B). Changes in
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anti-Dsg1 levels were consistent with the clinical response,
with a progressive decline over the time. Persistent high
titters in anti-Dsg3 were detected (ﬁgure 1C). The B-cell
count in peripheral blood dropped to levels below 1% and
remained that way during the follow-up. During this time
no complications were detected.
The unequivocal diagnosis of PF was made according to
clinical, histopathologic and immunofluorescence data. In
general, patients with PF have anti-Dsg1 antibodies but
not anti-Dsg3. The correlation between anti-Dsg profile
and clinical subtype is well established, but does not hold
true when the auto antibodies are non-pathogenic. In this
patient, although elevated levels of anti-Dsg3 were found,
there was no clinical phenotype for mucosal involvement.
Recently, researchers have found elevated anti-Dsg3 levels
by ELISA in a subset of patients with PF or its endemic vari-
ant fogo selvagem with no mucosal involvement [2]. The
non-pathogenic state could be explained by a decreased
affinity of the autoantibodies and epitope shift against dif-
ferent domains of desmoglein molecules [3].
The clinical response to rituximab was closely related to
the evolution of anti-Dsg1, dramatically decreased over the
time. However, in this patient persistently high levels of
non-pathogenic anti-Dsg3 were found. Indeed, persistent
high titers of anti-Dsg3 antibodies have been observed in
patients with clinically complete remission of pemphigus
vulgaris, treated with rituximab [4]. Some authors explain
this phenomenon by a rituximab affinity for auto-reactive
B cell clones [5]. Also, compelling evidence demonstrates
that epitopes bound by anti-Dsg autoantibodies determine
their pathogenic activities and disease activity in pemphi-
gus patients [3]. It has been demonstrated that sera from
pemphigus patients in complete remission after rituximab,
with persistent high levels of anti-Dsg3 antibodies, no
longer recognized the pathogenic epitopes that were tar-
geted during the active phase of the disease [4].
Rituximab is a monoclonal chimeric IgG antibody target-
ing the B-cell specific cell surface antigen CD20. From its
first use in PF, several case reports and small series have
been published. A search of English, German and French
literature found 20 PF patients treated with rituximab,
with partial or complete response in 95% (19/20) patients
[6]. However, prospective controlled trials are needed with
longer follow-up to assess the long-term efficacy and risks
of this treatment. 
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Porokeratosis ptychotropica
Porokeratosis is characterized by the proliferation of ker-
atinocytes, which are responsible for annular lesions that
exhibit an elevated hyperkeratotic ridge-like peripheral
border and an atrophic centre [1]. The characteristic his-
tological feature of porokeratosis is the presence of the
cornoid lamella that is represented by a compact column
of parakeratosis, whose cells originate from the stratum
corneum and superior epidermis and are formed at the
boundary between normal and abnormal epidermal cells
at the ridge of the plaque [1].
Six types of porokeratosis are distinguished, notably classi-
cal porokeratosis of Mibelli, linear porokeratosis, punctate
porokeratosis, disseminated superficial porokeratosis, dis-
seminated superficial actinic porokeratosis, porokeratosis
palmaris et plantaris disseminata. However, several other
clinical forms have been reported. Porokeratosis pty-
chotropica (PP) belongs to these rare types and is
characterized by symmetrically distributed reddish-brown
papules and plaques, mainly localized on the buttock and
the genital area [2]. Lesions tend to coalesce involving large
areas. PP may show a hyperkeratotic, verrucous or psori-
asiform appearance. Unlike porokeratosis of Mibelli, which
is generally asymptomatic, pruritus is often present in PP.
Moreover, all reported cases have been described in male
patients.
Here, we describe a 49-year-old man with a 2-year his-
tory of erythematous papules on the genital area. Lesions
involved the buttocks with a marked affinity to the fold
between the buttocks and thighs. New satellite lesions could
be observed at the edges of the involved areas. The patient
complained of pruritus and pain. There was no personal or
familial history of skin diseases. Routine hematological and
chemical evaluations were negative. Screening for HIV-1,
HIV-2 and syphilis were negative. PCR detection of HPV
DNA in skin lesions was negative. The possibility of fungal
infection was excluded with PAS staining. Physical exami-
nation revealed bilateral and symmetrical well-demarcated
hyperkeratotic, erythematous, brownish plaques involving
buttocks, genitals, top of the thighs and groin (ﬁgures 1A,B).
Histopathological examination of a biopsy showed multiple
compact columns of hyperkeratotic cells, the cornoid lamel-
lae (ﬁgure 1C). The granular layer was absent or poorly
